Tag: ARVO

A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss

sarah JonasFeature

A new approach to gene therapy resets cell homeostasis. Clinical trials to treat the retinal disorders Retinitis Pigmentosa, Stargardt’s, and Geographic Atrophy (late dry macular degeneration) are underway and showing promise.

jCyte Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy

sarah JonasResearch Results

jCyte’s presentation at ARVO 2021, demonstrated that retinitis pigmentosa patients treated with the 6 million cell dose of jCell therapy had significant gains in a broad range of visual function tests – BCVA, visual field (KVF), contrast sensitivity (CS), and low luminance mobility (LLMT) – all which measure important and different aspects of functional vision. jCyte also engaged the Cleveland Clinic to identify an anatomical biomarker for patient response to jCell therapy in retinitis pigmentosa, which will help guide the upcoming pivotal study.